

<b>MEDICAL POLICY</b>	<b>Cefaly Device for Treatment of Migraine Headaches</b>	
<b>Effective Date: 6/1/2020</b>   <div style="text-align: right;">6/1/2020</div>	Section: DME	Policy No: 181
	Technology Assessment Committee Approved Date: 10/14; 10/15 Medical Policy Committee Approved Date: 10/16; 12/17; 12/18; 12/19; 5/2020	
Medical Officer	Date	

**See Policy CPT/HCPCS CODE section below for any prior authorization requirements**

**SCOPE:**

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

**APPLIES TO:**

All lines of business

**BENEFIT APPLICATION**

Medicaid Members

*Oregon:* Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

**POLICY CRITERIA**

The Cefaly Supraorbital Transcutaneous Neurostimulator device is considered **investigational and not covered** as a treatment of any condition, including migraine headache.

Link to [Policy Summary](#)

**BILLING GUIDELINES**

Note: The following codes are not appropriate for the Cefaly device as they describe simulation using more than one lead:

- A4595
- E0720
- E0730

<b>MEDICAL POLICY</b>	<b>Cefaly Device for Treatment of Migraine Headaches</b>
-----------------------	--

**HCPCS CODES**

All Lines of Business	
<p>Unlisted Codes  All unlisted codes will be reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is billed related to services addressed in this policy then it will be <b>denied as not covered</b>.</p>	
A9270	Non-covered item or service
A9999	Miscellaneous dme supply or accessory, not otherwise specified

**DESCRIPTION**

Cefaly is a small, portable, battery-powered, supraorbital transcutaneous neurostimulator prescription device that resembles a plastic headband worn across the forehead and atop the ears. The device consists of an adhesive, gel-backed electrode that the patient places directly on the skin in the center of the forehead, connects the electrode to the generator, and then turns on a plastic-framed pulse generator. The pulse generator fits like a pair of glasses. A control button in the center of the device powers the unit and allows the patient to control the level of stimulation.

**REVIEW OF EVIDENCE**

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding the use of the Cefaly device as a treatment for migraine headaches. Below is a summary of the available evidence identified through March 2020.

Randomized Controlled Trials

Data from one, manufacturer-funded randomized controlled trial (RCT) indicated that between months 1 and 3 the number of headaches and use of acute migraine medication was reduced.<sup>1</sup> Authors concluded Cefaly was an effective and safe preventive therapy for migraine; however, the RCT did not demonstrate superiority over other preventive drug and non-drug antimigraine treatments. The trial also indicated that the device did not completely prevent migraines and the use of Cefaly did not reduce the severity of the headaches when they did occur.<sup>1</sup>

Non-Randomized Trials

- In 2013, Magis et al., published a patient satisfaction survey which showed that approximately 53% of patients were satisfied with the Cefaly device and would be willing to buy the device for continued use.<sup>2</sup> However, over 46% of the patients were dissatisfied with treatment and returned the device. A compliance check indicated that those who returned the device had utilized it for less than 50% of the recommended time. Authors did not report on the percent of utilization by satisfied patients.

- Recent studies (published between 2016-2018) regarding the use of the Cefaly device for treatment of migraine headache were identified; however, all were limited by small sample sizes (n=10-57), short follow-up periods (two hours to four months), unblinded study design, surrogate endpoints, and a lack of control groups.<sup>3-10</sup> Two unblinded studies<sup>9,10</sup> that reported small but statically significant improvements in clinical endpoints among patients using Cefaly, also called for larger, randomized, sham-controlled studies to verify findings. In one manufacturer-sponsored survey of active Cefaly users in Europe, nearly half (48%) of respondents stated that “Cefaly doesn’t provide sufficient relief” during a migraine attack.<sup>4</sup>

## CLINICAL PRACTICE GUIDELINES

### American Headache Society

In 2012, the American Headache Society did not address the use of Cefaly in their guidelines for the treatment of acute migraine headaches.<sup>11</sup>

### National Institute for Health and Care Excellence

In 2016, NICE published guidelines on, “(t)ranscutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine.” The guideline stated that while, “the evidence on efficacy is limited in quantity and quality,” transcutaneous stimulation devices may be an option for patients in, “special arrangements for clinical governance, consent and audit or research.” The guideline also recommended clinicians ensure that patients understand, “the uncertainty about the procedure’s efficacy.”<sup>12</sup>

### American Academy of Neurology

In 2018, the American Academy of Neurology affirmed their 2010 guidelines in which migraines were not mentioned as an indication for transcutaneous electric nerve stimulation.<sup>13</sup>

## CENTERS FOR MEDICARE & MEDICAID

As of 4/17/2020, two relevant Centers for Medicare & Medicaid guidance documents were identified (Local Coverage Article: Transcutaneous Electrical Nerve Stimulators (TENS) – Policy Article (A52520)<sup>14</sup> and Local Coverage Determination (LCD): Transcutaneous Electrical Nerve Stimulators (TENS) (L33802)).<sup>15</sup>

L33802 states that Transcutaneous Electrical Nerve Stimulators (TENS) therapy is approved only for acute post-operative pain, chronic low back pain and certain types of intractable pain. “Headache,” however, is one of the “conditions for which TENS therapy is not considered to be reasonable and necessary.”<sup>15</sup>

## POLICY SUMMARY

There is insufficient evidence to support Cefaly for the treatment of migraines. Studies investigating Cefaly currently suffer from uncontrolled and unblinded study designs, small patient populations, short follow-up periods a lack of clinical endpoints. No clinical practice guidelines specifically recommend Cefaly as a treatment for any condition. In addition, the one guideline that conditionally endorses transcutaneous electrical nerve stimulation does so despite an acknowledged lack of proven efficacy. Studies with results supporting the use of Cefaly in preventing and/or treating migraines also call for larger, randomized and controlled trials to verify their findings.

## INSTRUCTIONS FOR USE

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days notice of policy changes that are restrictive in nature.

The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

## REGULATORY STATUS

### Mental Health Parity Statement

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case.

### Food and Drug Administration

In 2016, the FDA approved the Cefaly Supraorbital Transcutaneous Neurostimulator through the 510(k) de novo premarket review pathway, as a prophylactic treatment of episodic migraine.<sup>16</sup> In 2017, the FDA cleared the Cefaly Dual and Cefaly Acute devices, for acute migraine treatment and prevention, as substantially equivalent to the predicate Cefaly device.

## REFERENCES

1. Schoenen J, Vandersmissen B, Jeanette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator. *A randomized controlled trial*. 2013;80(8):697-704
2. Magis D, Sava S, d'Elia TS, Baschi R, Schoenen J. Safety and patients' satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache

- treatment: a survey of 2,313 headache sufferers in the general population. *The journal of headache and pain*. 2013;14(1):95
3. Vecchio E, Gentile E, Franco G, Ricci K, de Tommaso M. Effects of external trigeminal nerve stimulation (eTNS) on laser evoked cortical potentials (LEP): A pilot study in migraine patients and controls. *Cephalalgia*. 2018;38(7):1245-1256
  4. Penning S, Schoenen J. A survey on migraine attack treatment with the CEFALY® device in regular users. *Acta Neurol Belg*. 2017;117(2):547-549
  5. Przeklasa-Muszyńska A, Skrzypiec K, Kocot-Kępska M, Dobrogowski J, Wiatr M, Mika J. Non-invasive transcutaneous Supraorbital Neurostimulation (tSNS) using Cefaly® device in prevention of primary headaches. *Neurologia i neurochirurgia polska*. 2017;51(2):127-134
  6. Di Fiore P, Bussone G, Galli A, et al. Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial. *Neurol Sci*. 2017;38(Suppl 1):201-206
  7. Russo A, Tessitore A, Esposito F, et al. Functional changes of the perigenual part of the anterior cingulate cortex after external trigeminal neurostimulation in migraine patients. *Frontiers in neurology*. 2017;8:282
  8. Magis D, D'Ostilio K, Thibaut A, et al. Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine. *Cephalalgia*. 2017;37(9):881-891
  9. Chou DE, Gross GJ, Casadei CH, Yugrakh MS. External Trigeminal Nerve Stimulation for the Acute Treatment of Migraine: Open-Label Trial on Safety and Efficacy. *Neuromodulation*. 2017;20(7):678-683
  10. Vikelis M, Dermitzakis EV, Spingos KC, Vasiliadis GG, Vlachos GS, Kararizou E. Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study. *BMC Neurol*. 2017;17(1):97
  11. Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. *Headache: The Journal of Head and Face Pain*. 2012;52(6):930-945
  12. National Institute for Health and Care Excellence. Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine. <https://www.nice.org.uk/guidance/ipg559>. Published 2016. Accessed 4/17/2020.
  13. American Academy of Neurology. Efficacy of Transcutaneous Electric Nerve Stimulation in the Treatment of Pain in Neurologic Disorders. <https://www.aan.com/Guidelines/home/GuidelineDetail/382>. Published 2010 (reaffirmed 2018). Accessed 4/17/2020.
  14. Centers for Medicare & Medicaid Services. Local Coverage Article: Transcutaneous Electrical Nerve Stimulators (TENS) - Policy Article (A52520). <https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=52520>. Published 2015. Accessed 4/17/2020.
  15. Centers for Medicare & Medicaid Services. Local Coverage Determination (LCD): Transcutaneous Electrical Nerve Stimulators (TENS) (L33802). <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33802>. Published 2015. Accessed 4/17/2020.
  16. U.S. Food and Drug Administration. 510(k) Premarket Notification - CEFALY®. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf16/K160237.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf16/K160237.pdf). Published 2016. Accessed 4/17/2020.